Loading company…
Nivalis Therapeutics develops small molecule therapies for cystic fibrosis and other inflammatory lung diseases.
Nivalis Therapeutics develops disease-modifying therapies for cystic fibrosis and other inflammatory lung diseases, using proprietary small molecule inhibitors of GSNOR. Founded in 2007 and headquartered in Boulder, US, the company's CEO is Charles Scoggin. It has raised a total of USD 88.55 mn, with its most recent deal an IPO on June 17, 2015.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in